Niagen Bioscience, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Niagen Bioscience, Inc.'s yearly results (2022–2025), compared with Consumer Defensive companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 54.3 times. Higher than 98% of Consumer Defensive companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 31% of its market value (net cash). Higher than 95% of Consumer Defensive companies in United States.
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 93% of Consumer Defensive companies in United States.
Cash quality
Profit Cash Ratio
$156Over the last 3 years, every $100 of reported profit came with $156 of operating cash.
Lower than 52% of Consumer Defensive companies in United States.
Self-Funding Ratio
54.3×Over the last 3 years its own operating cash covered its investment spending (capex) 54.3 times.
Higher than 98% of Consumer Defensive companies in United States.
Cash Locked Ratio
$15For every $100 of sales, $15 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $19 tied up three years earlier.
More money tied up than 65% of Consumer Defensive companies in United States.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 93% of Consumer Defensive companies in United States.
Growth Efficiency Ratio
$59Sales grew 80% in 3 years; of every extra $100 of sales, $59 became extra profit.
Higher than 89% of Consumer Defensive companies in United States.
Asset Productivity Ratio
+80% / +97%In 3 years sales changed by +80% while total assets changed by +97%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
13.5×Debt due within a year is covered 13.5 times by its yearly operating cash.
Higher than 79% of Consumer Defensive companies in United States.
Cash Cushion Ratio
+31%Cash, after subtracting all debt, equals 31% of its market value (net cash).
Higher than 95% of Consumer Defensive companies in United States.
Tangible Assets Ratio
95%Of every $100 the company owns, $95 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 76% of Consumer Defensive companies in United States.
Tangible Net Worth Ratio
93%Of every $100 of net worth, $93 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 81% of Consumer Defensive companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Niagen Bioscience, Inc. owes $0.23 for every $1 it owns. Net profit rose 103% in the year to Dec 2025.
Compared with Consumer Defensive companies in United States · latest annual results Dec 2025.
P/E ratio
13.3Investors pay $13.3 for every $1 of Niagen Bioscience, Inc.'s yearly profit, lower than 79% of Consumer Defensive companies in United States.
P/B ratio
2.42The share price is 2.42 times Niagen Bioscience, Inc.'s book value per share, higher than 54% of Consumer Defensive companies in United States.
Market cap
$199 MThe total market value of all of Niagen Bioscience, Inc.'s shares at today's price (share price × number of shares), smaller than 71% of Consumer Defensive companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$83 MWhat Niagen Bioscience, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.04Net worth divided by the number of shares. The share price of $2.52 is 2.4 times this, which is the P/B above.
Return on equity (ROE)
21.8%Niagen Bioscience, Inc. earned 21.8% on its shareholders' money over the last year, higher than 85% of Consumer Defensive companies in United States.
Owes vs Owns
0.23×Niagen Bioscience, Inc. owes $0.23 for every $1 it owns (low), lower than 92% of Consumer Defensive companies in United States.
Dividend yield
NoneNiagen Bioscience, Inc. does not currently pay a dividend.
Revenue growth
+30%Revenue rose 30% in the year to Dec 2025, and grew 22% a year on average over 3 years.
Profit growth
+103%Net profit rose 103% in the year to Dec 2025.
Profit margin
13.4%Niagen Bioscience, Inc. keeps $13 of every $100 of revenue as net profit.
Cash quality
0.8×Cash from Niagen Bioscience, Inc.'s business was 0.8× its reported profit in the year to Dec 2025 — less cash came in than the profit reported.
Cash vs debt
Net cashNiagen Bioscience, Inc. held $62 M more cash than debt (net cash) at Dec 2025.
Questions
What is Niagen Bioscience, Inc.'s P/E ratio?
Investors pay $13.3 for every $1 of Niagen Bioscience, Inc.'s yearly profit, lower than 79% of Consumer Defensive companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Niagen Bioscience, Inc.: $199 M ÷ $83 M (30 Jun 2026) = 2.4.
What is Niagen Bioscience, Inc.'s return on equity?
Niagen Bioscience, Inc. earned 21.8% on its shareholders' money over the last year, higher than 85% of Consumer Defensive companies in United States.
How much does Niagen Bioscience, Inc. owe compared with what it owns?
Niagen Bioscience, Inc. owes $0.23 for every $1 it owns (low), lower than 92% of Consumer Defensive companies in United States.
Does Niagen Bioscience, Inc. pay a dividend?
No. Niagen Bioscience, Inc. does not currently pay a dividend.
Is Niagen Bioscience, Inc.'s revenue growing?
Revenue rose 30% in the year to Dec 2025, and grew 22% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.